RHYTHM PHARMACEUTICALS, INC. Operating Income
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Operating Income of -$48.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$48.55M.
- RHYTHM PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$52.36M.
- RHYTHM PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$47.06M.
- RHYTHM PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$52.65M.
- RHYTHM PHARMACEUTICALS, INC. operating income (loss) for fiscal 2025 was -$192.02M.
- RHYTHM PHARMACEUTICALS, INC. operating income (loss) for fiscal 2024 was -$265.50M.
- RHYTHM PHARMACEUTICALS, INC. operating income (loss) for fiscal 2023 was -$184.36M.
- RHYTHM PHARMACEUTICALS, INC. operating income (loss) for fiscal 2022 was -$179.16M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$48.55M 10-Q · filed 2026-08-04 | -$100.91M 10-Q · filed 2026-08-04 | -$147.98M derived: sum of 3 quarters · filed 2026-08-04 | -$200.63M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$52.36M 10-Q · filed 2026-05-05 | -$99.42M derived: sum of 2 quarters · filed 2026-05-05 | -$152.08M derived: sum of 3 quarters · filed 2026-05-05 | -$197.37M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$47.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$99.72M derived: sum of 2 quarters · filed 2026-02-26 | -$145.01M derived: sum of 3 quarters · filed 2026-08-04 | -$192.02M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$52.65M 10-Q · filed 2025-11-04 | -$97.95M derived: sum of 2 quarters · filed 2026-08-04 | -$144.95M 10-Q · filed 2025-11-04 | -$186.21M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$45.30M 10-Q · filed 2026-08-04 | -$92.30M 10-Q · filed 2026-08-04 | -$133.56M derived: sum of 3 quarters · filed 2026-08-04 | -$177.44M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$47.00M 10-Q · filed 2026-05-05 | -$88.26M derived: sum of 2 quarters · filed 2026-05-05 | -$132.14M derived: sum of 3 quarters · filed 2026-05-05 | -$172.62M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$41.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$85.14M derived: sum of 2 quarters · filed 2026-02-26 | -$125.62M derived: sum of 3 quarters · filed 2026-02-26 | -$265.50M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$43.88M 10-Q · filed 2025-11-04 | -$84.36M derived: sum of 2 quarters · filed 2025-11-04 | -$224.25M 10-Q · filed 2025-11-04 | -$265.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$40.48M 10-Q · filed 2025-08-05 | -$180.36M 10-Q · filed 2025-08-05 | -$221.63M derived: sum of 3 quarters · filed 2026-02-26 | -$265.58M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$139.89M 10-Q · filed 2025-05-07 | -$181.15M derived: sum of 2 quarters · filed 2026-02-26 | -$225.10M derived: sum of 3 quarters · filed 2026-02-26 | -$271.71M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$41.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$85.22M derived: sum of 2 quarters · filed 2026-02-26 | -$131.82M derived: sum of 3 quarters · filed 2026-02-26 | -$184.36M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$43.95M 10-Q · filed 2024-11-06 | -$90.56M derived: sum of 2 quarters · filed 2024-11-06 | -$143.09M 10-Q · filed 2024-11-06 | -$185.19M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$46.60M 10-Q · filed 2024-08-06 | -$99.13M 10-Q · filed 2024-08-06 | -$141.24M derived: sum of 3 quarters · filed 2025-02-28 | -$180.50M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$52.53M 10-Q · filed 2024-05-07 | -$94.63M derived: sum of 2 quarters · filed 2025-02-28 | -$133.90M derived: sum of 3 quarters · filed 2025-02-28 | -$179.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$42.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$81.37M derived: sum of 2 quarters · filed 2025-02-28 | -$126.47M derived: sum of 3 quarters · filed 2025-02-28 | -$179.16M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$39.27M 10-Q · filed 2023-11-08 | -$84.36M derived: sum of 2 quarters · filed 2023-11-08 | -$137.05M 10-Q · filed 2023-11-08 | -$188.04M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$45.10M 10-Q · filed 2023-08-01 | -$97.79M 10-Q · filed 2023-08-01 | -$148.78M derived: sum of 3 quarters · filed 2024-02-29 | -$193.02M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$52.69M 10-Q · filed 2023-05-02 | -$103.68M derived: sum of 2 quarters · filed 2024-02-29 | -$147.92M derived: sum of 3 quarters · filed 2024-02-29 | -$188.35M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$50.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$95.23M derived: sum of 2 quarters · filed 2024-02-29 | -$135.66M derived: sum of 3 quarters · filed 2024-02-29 | -$170.06M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$44.24M 10-Q · filed 2022-11-08 | -$84.67M derived: sum of 2 quarters · filed 2022-11-08 | -$119.07M 10-Q · filed 2022-11-08 | -$154.14M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$40.43M 10-Q · filed 2022-08-03 | -$74.83M 10-Q · filed 2022-08-03 | -$109.90M derived: sum of 3 quarters · filed 2023-03-01 | -$144.19M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$34.40M 10-Q · filed 2022-05-03 | -$69.47M derived: sum of 2 quarters · filed 2023-03-01 | -$103.75M derived: sum of 3 quarters · filed 2023-03-01 | -$135.67M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$35.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$69.36M derived: sum of 2 quarters · filed 2023-03-01 | -$101.28M derived: sum of 3 quarters · filed 2023-03-01 | -$136.57M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$34.28M 10-Q · filed 2021-11-02 | -$66.20M derived: sum of 2 quarters · filed 2021-11-02 | -$101.50M 10-Q · filed 2021-11-02 | -$135.73M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$31.92M 10-Q · filed 2021-08-03 | -$67.22M 10-Q · filed 2021-08-03 | -$101.44M derived: sum of 3 quarters · filed 2022-03-01 | -$138.55M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$35.30M 10-Q · filed 2021-05-03 | -$69.52M derived: sum of 2 quarters · filed 2022-03-01 | -$106.63M derived: sum of 3 quarters · filed 2022-03-01 | -$150.78M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$34.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$71.33M derived: sum of 2 quarters · filed 2022-03-01 | -$115.48M derived: sum of 3 quarters · filed 2022-03-01 | -$146.00M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$37.11M 10-Q · filed 2020-11-02 | -$81.26M derived: sum of 2 quarters · filed 2020-11-02 | -$111.78M 10-Q · filed 2020-11-02 | -$138.93M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$44.15M 10-Q · filed 2020-08-03 | -$74.67M 10-Q · filed 2020-08-03 | -$101.82M derived: sum of 3 quarters · filed 2021-03-01 | -$121.06M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$30.52M 10-Q · filed 2020-05-04 | -$57.67M derived: sum of 2 quarters · filed 2021-03-01 | -$76.92M derived: sum of 3 quarters · filed 2021-03-01 | -$91.94M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$27.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$46.40M derived: sum of 2 quarters · filed 2021-03-01 | -$61.42M derived: sum of 3 quarters · filed 2021-03-01 | -$78.42M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$19.24M 10-Q · filed 2019-11-01 | -$34.27M derived: sum of 2 quarters · filed 2019-11-01 | -$51.27M 10-Q · filed 2019-11-01 | -$62.25M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$15.02M 10-Q · filed 2019-07-29 | -$32.02M 10-Q · filed 2019-07-29 | -$43.01M derived: sum of 3 quarters · filed 2020-03-02 | -$51.29M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$17.00M 10-Q · filed 2019-05-03 | -$27.98M derived: sum of 2 quarters · filed 2020-03-02 | -$36.27M derived: sum of 3 quarters · filed 2020-03-02 | -$43.02M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | -$10.98M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$19.27M derived: sum of 2 quarters · filed 2020-03-02 | -$26.02M derived: sum of 3 quarters · filed 2020-03-02 | -$32.41M 10-K · filed 2020-03-02 |
| 2017-09-30 | -$8.29M 10-Q · filed 2018-11-09 | -$15.04M derived: sum of 2 quarters · filed 2018-11-09 | -$21.43M 10-Q · filed 2018-11-09 | -$29.80M derived: sum of 4 quarters · filed 2019-03-08 |
| 2017-06-30 | -$6.75M 10-Q · filed 2018-08-08 | -$13.14M 10-Q · filed 2018-08-08 | -$21.52M derived: sum of 3 quarters · filed 2019-03-08 | -$27.92M derived: sum of 4 quarters · filed 2019-03-08 |
| 2017-03-31 | -$6.39M 10-Q · filed 2018-05-14 | -$14.76M derived: sum of 2 quarters · filed 2019-03-08 | -$21.16M derived: sum of 3 quarters · filed 2019-03-08 | |
| 2016-12-31 | -$8.38M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | -$14.78M derived: sum of 2 quarters · filed 2019-03-08 | -$25.91M 10-K · filed 2019-03-08 | |
| 2016-09-30 | -$6.40M 10-Q · filed 2017-11-14 | -$17.53M 10-Q · filed 2017-11-14 | ||
| 2015-12-31 | -$10.57M 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |